TrialClinical cancer research : an official journal of the American Association for Cancer Research2022

A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.

Yuri Taniguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.